PHILADELPHIA - Beatrice H. Hahn, MD, a professor of Medicine and Microbiology in the Perelman School of Medicine at the University of Pennsylvania, and her colleagues have been studying the origin of HIV-1 in non-human primates for decades. They previously discovered that simian immunodeficiency viruses (SIVs) infecting wild-living chimpanzees and gorillas jumped the species barrier into humans on four occasions, one of which spawned the AIDS pandemic. Understanding how these viruses are transmitted within and between species may reveal clues for novel vaccine strategies in humans.
HIV and SIV infect and kill immune cells called CD4 T cells, a process that ultimately leads to AIDS. Publishing this week in the Proceedings of the National Academy of Sciences, Hahn's lab and an international team of collaborators, found that the CD4 surface protein, which is used by HIV and SIV as the receptor to enter immune cells, is highly variable among wild chimpanzees. Characterizing fecal samples from over 500 chimpanzees across sub-Saharan Africa, they found, to their surprise, nine CD4 variants. They went on to demonstrate that this diversity in CD4 protects chimpanzees from their own strain of SIV, as well as potentially dangerous SIVs carried by other monkey species on which they prey.
SIVs infect over 40 primate species in sub-Saharan Africa and can be deadly. Hahn's group showed in previous studies that SIV-infected chimpanzees in the wild have a higher mortality than uninfected chimpanzees and can develop an AIDS-like disease, like that in humans.
"CD4 is known to have evolved rapidly in primates, but the reason for this has remained unclear," said Hahn. "Now we find that mutations in the chimpanzee CD4 reduce susceptibility to SIV infection, which could provide a selective advantage to apes bearing these CD4 variants."
To get into host cells, HIV and SIV use their outermost, or envelope, glycoprotein to bind to the outermost region of the CD4 receptor. "To counteract this, chimpanzees have evolved several mutations in this CD4 domain that blocks this interaction," said co-first author Ronnie Russell, a doctoral student in Hahn's lab.
The team found that these mutations include amino acid changes in contact residues as well as the addition of bulky sugar molecules, called glycans, at the CD4-envelope binding interface. "Glycans on the chimpanzee CD4 clash with glycans on the SIV envelope, which impedes virus entry into the cell," said co-first author Frederic Bibollet-Ruche, PhD, a research assistant professor of Microbiology in Hahn's lab. This type of glycan-glycan interaction has not been seen before as an anti-viral mechanism.
Unlike chimps, humans lack protective glycans on the virus-binding domain of the CD4 protein. "This may explain our relative susceptibility to SIV cross-species infection, which has occurred at least a dozen times within the last century or so," said co-author Paul Sharp, PhD, an evolutionary biologist at the University of Edinburgh.
Although chimpanzee SIVs are highly divergent from their human counterparts, previous work by the Hahn group showed that they share unexpected antibody cross-reactivity with HIV at the very tip, or apex, of their envelope spike. This finding raised the possibility that HIV and SIV envelopes could be used in combination to focus a protective antibody response to this conserved epitope in a vaccine.
"Understanding how the diversification of the chimpanzee CD4 affects the structure and function of the chimpanzee SIV envelope has practical implications for AIDS vaccine development," says co-author George Shaw, MD, PhD, a professor of Medicine and Microbiology at Penn.
The research consortium that carried out this work included primatologists dedicated to the conservation of wild chimpanzees. "The many samples provided by our collaborators have been instrumental in uncovering the tricks that chimpanzees use to ward off SIV," said Hahn. "Ultimately, this may help in the design of better HIV vaccines. It's a long shot, but it has certainly brought all our work on the biology and evolution of the ape precursors of HIV full circle."
This work was supported by the National Institutes of Health (R01 AI120810, R01 AI091595, R37 AI050529, UM1 AI100645, UM1 AI26620, P30 AI045008, T32 AI 007632), the Yerkes National Primate Research Center (P51 RR-000165), the Southwest National Primate Research Center (P51 RR013986, P51 OD011133), and a Canadian Institutes of Health Research Foundation (#352417).
This study was completed in collaboration with researchers from the National Institute of Allergy and Infectious Diseases, University of Edinburgh, University of Alabama at Birmingham, L'Université de Montréal, Robert Koch Institute, Max Planck Institute for Evolutionary Anthropology, Chimbo Foundation, Projet Primates France, Centre de Conservation pour Chimpanzés, University of Zurich, Sanaga-Yong Chimpanzee Rescue Center, Drexel University, University of New Mexico, Washington University, Wildlife Conservation Society, Lincoln Park Zoo, The Jane Goodall Institute, Liverpool John Moores University, University of Kisangani, Franklin and Marshall College, and Duke University.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $7.8 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $405 million awarded in the 2017 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; Penn Wissahickon Hospice; and Pennsylvania Hospital - the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine, and Princeton House Behavioral Health, a leading provider of highly skilled and compassionate behavioral healthcare.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2017, Penn Medicine provided $500 million to benefit our community.